• Nimase Pratiksha Ashok
• Chaudhari Datta Manjaba
• Gund Vaibhav Balu
• Pawar Dattatray Gorakh
• Gujar Sagar Vijay

The treatment of acute or chronic disease has been primarily achieved by administering drugs to patients using various pharmaceutical dosage forms, including tablets, capsules, pills, suppositories, creams, ointments, liquids, sprays and injectables , as a drugs. carriers. this sort of drug delivery system is understood to supply rapid release of drug or immediate release product. Such immediate release products end in relatively rapid drug absorption and associated pharmacodynamic effects. However, once drug absorption from the dosage form is complete, the plasma concentrations of the drug decrease supported the pharmacokinetic profile of the drug. Eventually, the plasma concentrations of the drug drop below the minimum effective plasma concentration (MEC), leading to a loss of therapeutic activity. Before now is reached, another dose is typically given if a protracted therapeutic effect is desired. an alternate to administering another dose is to use a dosage form that gives sustained release of the drug and thereby maintains plasma drug concentrations beyond what's typically seen with immediate-release dosage forms. In recent years, several modified versions and / or the time of release of the drug. After the 20th century, the look for a replacement drug remained thanks to the value of researching the new drug. Therefore, pharmaceutical industries and academic laboratories have focused on creating a replacement drug delivery system / or modified release dosage forms instead of research and development of a replacement drug. The rationale for a protracted drug delivery system is to optimize the biopharmaceutical, pharmacokinetic and pharmacodynamic properties of a drug such its usefulness is maximized by reducing side effects and treating or controlling the disease as quickly as possible using the foremost little ones.

chlorpromazine, Microcrystalline Cellulose, Magnesium Stearate.

"Formulation and Evaluation of sustained release tablet chlorpromazine", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 7, page no.d220-d232, July-2022, Available :http://www.jetir.org/papers/JETIR2207325.pdf

"Formulation and Evaluation of sustained release tablet chlorpromazine", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 7, page no. ppd220-d232, July-2022, Available at : http://www.jetir.org/papers/JETIR2207325.pdf